Cftr Trikafta denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Prior Authorization for Trikafta — and How to Navigate It

A prior-authorization (PA) denial from UnitedHealthcare (UHC) for Trikafta (elexacaftor/tezacaftor/ivacaftor) means either that prior authorization was not obtained before the prescription was dispensed, or that a PA request was submitted but not approved. Prior authorization is UHC's mechanism for verifying that a patient meets its coverage criteria before the plan pays — it is a procedural gate, not a clinical judgment about the drug itself. With the right documentation, most PA requests for Trikafta are approvable.

## Why This Denial Happens

Trikafta is a high-cost specialty drug. UHC requires that the prescribing clinician submit documentation confirming diagnosis, CFTR mutation type, age, clinical status, and — in some policy versions — prior-treatment history. PA denials occur when the submission is incomplete, when required clinical fields are missing, or when the submission did not occur before the claim was adjudicated.

## Your Federal Appeal Rights

• PA reconsideration / peer-to-peer: Before filing a formal appeal, the prescribing clinician should request a peer-to-peer review with UHC's medical reviewer. This is a direct clinical conversation and resolves many PA denials before the formal appeal stage.
• Internal appeal: Under ERISA §503 or applicable state law, a PA denial is formally appealable. File within the deadline shown on the denial letter.
• Retroactive authorization: If the drug was dispensed without prior PA and the patient is experiencing an urgent situation, ask UHC about its retroactive authorization process for urgent or emergent situations.
• External review (ACA §2719): If the internal appeal is denied, independent external review is available within approximately four months of the final denial notice.
• Expedited review: Available within 72 hours when delay would seriously jeopardize health — request expedited PA as well as expedited appeal.

## Documentation to Gather

1. Complete PA request form — ensure every required field is filled, including diagnosis code, CFTR mutation genotype, patient age, and clinical status. 2. Genetic testing report — the actual laboratory report confirming the mutation type that falls within the FDA-approved indication for Trikafta. 3. Clinical chart notes — recent pulmonologist or CF specialist notes documenting lung function, exacerbation history, nutritional status, and treatment history. 4. Prescriber medical-necessity letter — a detailed letter explaining why Trikafta is medically necessary for this patient, referencing UHC's PA criteria individually. 5. Prior-treatment documentation — if UHC's PA criteria require prior therapy, document all prior CF treatments with dates, duration, and outcomes.

## Criteria-Mapping Structure

Obtain UHC's current PA criteria for Trikafta and the FDA prescribing label. Prepare a submission table:

| UHC PA Criterion | Satisfying Documentation | |---|---| | Each criterion in UHC's PA form or medical policy | Specific chart note, test result, or prescriber statement | | Mutation-indication match | Genetic testing report | | Clinical necessity | Lung function data + exacerbation history |

Submitting a complete, criterion-mapped package on the first PA request — or resubmitting one on appeal — dramatically reduces the likelihood of a second denial.